Sentrx CEO Resigns

Charles T. Saldarini has resigned from his position at Sentrx as chief executive officer and chairman of the board to pursue efforts with his own company, The Charles T. Saldarini Group. Effective immediately, the company’s president and general manager, Michael O’Gorman, has been appointed to serve in these roles. Mr. Saldarini will remain available as a consultant and advisor.  

“My experience with Sentrx has been excellent,” said Mr. Saldarini. “To be part of an organization that is helping bring the industry’s focus on drug safety as a commercial value driver into a sharper, more critical view has been a privilege. We do important work here, and I am pleased to leave knowing I have helped shape our approach and connect our strategy with a structure that consistently delivers that work.”

“Chuck has made tremendous contributions to Sentrx,” said Mr. O’Gorman. “Under his leadership, the company made significant improvements in focusing on customer needs, market positioning, operating culture and overall business results, including increased revenues and profitability. Chuck’s vision for solving customer needs with leading edge technology solutions will continue to be a critical element of our plans going forward. The staff at Sentrx wishes him well and we are extremely grateful for his contributions.”